Showing results (261-270 of 4,380) with videos related to
Sort By:
Pageof 438
ACS Medicinal Chemistry Letters|July 21, 2015
BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536Lijia Chen, Jeremy L Yap, Makoto Yoshioka, et al.ACS Medicinal Chemistry Letters|July 21, 2015
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 InhibitorAlexei S Karpov, Payman Amiri, Cornelia Bellamacina, et al.ACS Medicinal Chemistry Letters|July 21, 2015
Fragment-Based Discovery of Potent and Selective DDR1/2 InhibitorsChristopher W Murray, Valerio Berdini, Ildiko M Buck, et al.ACS Medicinal Chemistry Letters|July 21, 2015
Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo EfficacyDilip K Tosh, Steven Crane, Zhoumou Chen, et al.ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer AgentYong Liu, Radoslaw Laufer, Narendra Kumar Patel, et al.ACS Medicinal Chemistry Letters|June 24, 2015
Target (In)Validation: A Critical, Sometimes Unheralded, Role of Modern Medicinal ChemistryRamzi F SweisACS Medicinal Chemistry Letters|June 24, 2015
MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A InhibitorsTodd B Sells, Ryan Chau, Jeffrey A Ecsedy, et al.ACS Medicinal Chemistry Letters|June 24, 2015
Structure-Activity Relationship Studies of 3-epi-Deoxynegamycin Derivatives as Potent Readthrough Drug CandidatesKeisuke Hamada, Akihiro Taguchi, Masaya Kotake, et al.ACS Medicinal Chemistry Letters|June 24, 2015
Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor SeriesJoachim Rudolph, Ignacio Aliagas, James J Crawford, et al.ACS Medicinal Chemistry Letters|June 20, 2020
Can Drug Repositioning Work as a Systematical Business Model?Jianan HuangPageof 438